Education
About Us
Working with TipRanks
Follow Us
Genmab (Otc) (GMAB)
:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.24 - $30.41
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.66M
Market Cap
$11.88B
Enterprise Value$13.14B
Total Cash (Recent Filing)kr9.86B
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)10.9
Beta0.61
Next Earnings
May 08, 2025EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.77
Shares Outstanding641,203,900
10 Day Avg. Volume1,960,997
30 Day Avg. Volume1,661,604
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)N/A
Price to Sales (P/S)4.15
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$60.68Price Target Upside214.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Genmab News
PremiumCompany Announcements
Genmab Reports Strong Q1 2025 DARZALEX Sales---
Bulls Say, Bears Say
Bulls Say
EarningsGenmab recorded a diluted net income of DKK121.36 per share, which exceeded previous forecasts.
Future Growth PotentialWith a steady cadence of Phase III readouts beginning in 2026 and potential for nearly $6 billion in revenues in 2032, the first full year post-Darzalex royalties, analyst is upgrading shares of Genmab to Outperform.
Product ApprovalThe European Commission approved an indication extension of the combination of subcutaneous DARZALEX + bortezomib, lenalidomide, and dexamethasone in 1L multiple myeloma patients.
Bears Say
Partnership DecisionsJohnson & Johnson decided not to exercise its option to license Genmab's HexaBody-CD38 due to non-significant Phase 2 data results.
Product Safety And TolerabilityGEN3014 showed deeper responses than Darzalex Faspro but was associated with an inferior safety and tolerability profile.
Strategic DecisionsGMAB announced they will not pursue further clinical development of GEN3014 after a strategic assessment.
---
Ownership Overview
―
Insiders
1.17% Mutual Funds
2.39% Other Institutional Investors
95.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab (Otc)’s price range in the past 12 months?
Genmab (Otc) lowest stock price was $17.23 and its highest was $30.41 in the past 12 months.
What is Genmab (Otc)’s market cap?
Genmab (Otc)’s market cap is $11.88B.
When is Genmab (Otc)’s upcoming earnings report date?
Genmab (Otc)’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were Genmab (Otc)’s earnings last quarter?
Genmab (Otc) released its earnings results on Feb 12, 2025. The company reported $0.851 earnings per share for the quarter, beating the consensus estimate of $0.374 by $0.477.
Is Genmab (Otc) overvalued?
According to Wall Street analysts Genmab (Otc)’s price is currently Undervalued.
Does Genmab (Otc) pay dividends?
Genmab (Otc) does not currently pay dividends.
What is Genmab (Otc)’s EPS estimate?
Genmab (Otc)’s EPS estimate is 0.21.
How many shares outstanding does Genmab (Otc) have?
Genmab (Otc) has 641,203,900 shares outstanding.
What happened to Genmab (Otc)’s price movement after its last earnings report?
Genmab (Otc) reported an EPS of $0.851 in its last earnings report, beating expectations of $0.374. Following the earnings report the stock price went up 4.235%.
Which hedge fund is a major shareholder of Genmab (Otc)?
Currently, no hedge funds are holding shares in GMAB
---
Genmab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.68 (214.08% Upside)
$60.68 (214.08% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 307.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.97%
12-Months-Change
Fundamentals
Return on Equity
23.16%
Trailing 12-Months
Asset Growth
21.65%
Trailing 12-Months
Company Description
Genmab (Otc)
Genmab (GMAB) is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Operating primarily in the biotechnology and pharmaceutical sectors, Genmab's core products include proprietary antibody technology platforms and a pipeline of antibody-based drug candidates that address significant unmet medical needs.
---
GMAB Company Deck
---
GMAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with significant revenue and profit growth, driven by the success of commercialized medicines like EPKINLY and TIVDAK. The company has a robust pipeline with strategic investments and provided optimistic guidance for 2025. However, there are minor concerns about EPKINLY's flat sales in Q4 and the company's dependency on key products amid competitive pressures.Read More>---
GMAB Stock 12 Month Forecast
Average Price Target
$60.68
▲(214.08% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-17.26%
reiterated a buy rating 29 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -17.26% per trade.
---